康柏西普玻璃体腔注射辅助25G玻璃体切割手术治疗增殖性糖尿病视网膜病变的疗效观察

目的观察康柏西普玻璃体腔注射辅助25G玻璃体切割手术治疗增殖性糖尿病视网膜病变(PDR的疗效。方法回顾性分析52例(52眼)需行玻璃体切割的PDR患者临床资料,按手术前7 d是否行玻璃体腔注射康柏西普分为治疗组25例(25眼)和对照组27例(27眼)。治疗组在术前7 d予以康柏西普玻璃体腔注射,对照组术前不给予康柏西普注射,两组均行相同的25G微创玻璃体切割手术治疗。观察比较两组患者手术时间、术中并发症和术后3个月最佳矫正视力(BCVA)差异。结果治疗组手术时间、术中出血数、术中电凝数、医源性视网膜损伤数、硅油填充数均显著少于对照组(P <0.05)。治疗组术后3个月BCVA显著优于对照组(P <0.05)。两组均无其他全身不良反应。结论术前7 d给予玻璃体腔注射康柏西普辅助治疗,能有效减少25G微创玻璃体切割术治疗PDR的手术时间和术中并发症,并改善术后视力。

Clinical efficacy of 25G pars plana vitrectomy combined with intravitreal Conbercept pretreatment for proliferative diabetic retinopathy

Objective To evaluate the clinical efficacy of 25 G pars plana vitrectomy combined with intravitreal Conbercept pretreatment for proliferative diabetic retinopathy(PDR).Methods The clinical data of 52 patients(52 eyes) with PDR treated with pars plana vitrectomy were retrospectively analyzed.All the patients were divided into experimental group(n = 25,25 eyes) and control group(n = 27,27 eyes) according to whether or not they received intravitreal Conbercept on day 7 before pars plana vitrectomy.The overall surgical time,intraoperative complications and the best corrected visual acuity(BCVA) for three months postoperatively were compared between the two groups.Results The average surgical time and the number of intraoperative bleeding,intraoperative coagulation,iatrogenic retinal injury,and silicone oil filling in the experimental group were significantly less than those in the control group(P < 0.05).The BCVA of the experimental group was significantly better than that of the control group 3 months after operation(P < 0.05).No other systemic adverse reactions were observed in the two groups.Conclusion Intravitreal Conbercept can significantly reduce the operative time and the intraoperative complications and improve the postoperative vision for the patients with PDR 7 days before 25 G pars plana vitrectomy.